What's the duration of remission with ruxolitinib azacitidine?

How long does remission last with ruxolitinib plus azacitidine?

Ruxolitinib combined with azacitidine induces responses in patients with myelofibrosis, myelodysplastic syndromes, or acute myeloid leukemia, but reported durations vary widely depending on disease subtype, risk group, and follow-up length. In myelofibrosis patients, median overall response duration has been reported as 12 months when the agents are used together [1]. Median progression-free survival reaches 15 months in manchen patients, but this figure is drawn from small single-arm studies rather than large randomized trials.

What happens when patients stop taking ruxolitinib and azacitidine?

Patients who ablate their therapy often experience rapid disease rebound. In myelofibrosis, symptoms and spleen size grow back quickly after stopping ruxolitinib alone, and similar behavior occurs with the combination. In acute myeloid leukemia, relapse occurs within months after stopping or discontinuing the pair.

Why are companies challenging patents on ruxolitinib?

Ruxolitinib is already generic in some markets and has patent challenges across multiple jurisdictions. Companies seeking biosimilar or generic versions of the active ingredient seek to shorten the exclusivity period of the drug itself. Companies are also challenging patents on ruxolitinib plus azacitidine combinations, especially in myelofibrosis and myelodysplastic syndromes applications.

When does the ruxolitinib patent expire?

The primary U.S. compound patent covering ruxolitinib itself expires in 2026 [2].